Story

Eli Lilly Sues Six Companies Over Alleged Sales of Unapproved Obesity Drug Retatrutide

ENTHMSVIIDZHZH-TWJAKOHI
Aug 12, 20262 min read
Eli Lilly Sues Six Companies Over Alleged Sales of Unapproved Obesity Drug Retatrutide
Text size
Background

Eli Lilly (LLY) announced Wednesday it has filed six lawsuits against U.S.-based companies for allegedly selling unauthorized, black-market versions of its experimental obesity drug, retatrutide. The legal action marks an escalation in the drugmaker's efforts to combat the illicit sale of its products before the highly anticipated treatment has received regulatory approval.

Details of the Lawsuits

The lawsuits target a range of businesses, including medical spas, compounding pharmacies, and online sellers. According to Lilly, the defendants named in the filings are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide Co.

Lilly stated that these entities marketed and sold products claiming to be retatrutide, despite the fact that the drug is still undergoing Phase 3 clinical trials for obesity and type 2 diabetes. The company emphasized that no global regulator, including the U.S. Food and Drug Administration (FDA), has approved the compound for human use.

Regulatory Context and Company Stance

The legal action follows a June statement from the FDA, which clarified that the sale of unapproved versions of GLP-1 products like retatrutide is illegal and that they cannot be lawfully compounded. Lilly is working to protect both its intellectual property and potential patients from unverified substances.

Sample IUX Markets – In-articleAd

"What is being sold on the black market is not a medicine – it is entirely unverified, unapproved and not worth the risk," said Lilly Chief Medical Officer Dr. David Hyman in a statement. The company also noted it has referred more than 200 individuals and entities to law enforcement and regulatory bodies, including the FDA and the Department of Justice.

The Growing Black Market

Surging demand for new weight-loss treatments has fueled a significant black market for products claiming to be GLP-1 drugs. The scale of the issue is highlighted by data from U.S. Customs and Border Protection, which told Reuters it intercepted over 690 shipments of illicit GLP-1 drugs in fiscal year 2025. That figure more than doubled in the month of July alone, with over 1,400 seizures.

Lilly officials warned of the dangers associated with these unregulated products. "Every single time that someone takes one of these, they’re exposing themselves to a huge amount of risk," said Dr. Max Denning, an associate vice president at the company.

Read next

More on Stocks
Back to latest news

LATEST